Pairwise ORs (95% CrI) for gaining ≥15 letters from baseline (random treatment effects model)
| Comparator | Sham | Ranibizumab 0.5 mg PRN | Aflibercept 2q4 | Laser photocoagulation | Dexamethasone 0.7 mg implant | Ranibizumab 0.5 mg PRN+laser photocoagulation |
|---|---|---|---|---|---|---|
| Sham | − | |||||
| Ranibizumab 0.5 mg PRN | 3.53 (1.02 to 12.67)* | − | 1.06 (0.16 to 8.94) | 3.24 (1.03 to 12.56)* | ||
| Aflibercept 2q4 | 3.38 (0.28 to 31.36) | 0.95 (0.11 to 6.17) | − | 3.07 (0.63 to 14.75) | ||
| Laser photocoagulation | 1.11 (0.17 to 5.68) | 0.31 (0.08 to 0.97)* | 0.33 (0.07 to 1.59) | − | ||
| Dexamethasone 0.7 mg implant | 1.22 (0.35 to 4.38) | 0.35 (0.09 to 1.24) | 0.36 (0.04 to 4.54) | 1.11 (0.21 to 7.39) | − | |
| Ranibizumab 0.5 mg PRN+laser photocoagulation | 3.18 (0.43 to 20.98) | 0.89 (0.19 to 3.76) | 0.94 (0.11 to 8.85) | 2.87 (0.67 to 13.88) | 2.59 (0.33 to 17.21) | − |
*p<0.05.
Pairwise ORs indicate the relative treatment effect for the treatments compared in the network meta-analysis. A statistically significant OR greater than 1 indicates that the treatment in the corresponding row is superior to the treatment in the corresponding column.
Studies included in the base-case analysis are VIBRANT,12 BRAVO,9 BRIGHTER,32 COMRADE-B,33 Tan et al,27 Battaglia Parodi et al,8 GENEVA.14
2q4, 2 mg monthly; CrI, credible interval; PRN, pro re nata (as needed).